PhotonPharma Inc., a biopharmaceutical company pioneering personalized cancer immunotherapies, today announced that patient recruitment has opened for its Phase 1 clinical trial evaluating Innocell™ ...

PhotonPharma Inc., a biopharmaceutical company pioneering personalized cancer immunotherapies, today announced that patient recruitment has opened for its Phase 1 clinical trial evaluating Innocelltm ...

OVATION 3 is IMUNON’s pivotal Phase 3 study of IMMN-001, an IL-12 gene-mediated immunotherapy, in women with advanced stage epithelial ovarian cancer. The study is supported with unprecedented overall ...

Researchers have created a comprehensive single-cell atlas of the human breast, which uncovers diverse cell types linked to ...

Preclinical study findings point to new possibilities for strategies for treating metastatic TNBC patients for whom there are no specific therapies.

Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable ...

There’s currently no reliable screening test for ovarian cancer, meaning that most cases are caught at an advanced stage, ...

A new study discovers that early pregnancy in mice reduces buildup of ‘confused’ cells that could lead to breast cancer later in life.

Ovarian cancer is characterized by uncontrolled growth of cells in the ovaries. It can progress to another part of the body ...

Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, ...

Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., ...

Breast cancer (BC) is the most common cancer and the second leading cause of cancer death in women. It is a highly variable disease, defined as a malignancy of the epithelial ducts in breast tissue.